Envista (NYSE:NVST) Price Target Raised to $34.00

Envista (NYSE:NVST) had its price objective hoisted by Barclays from $24.00 to $34.00 in a research report released on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other research firms also recently weighed in on NVST. Morgan Stanley set a $19.00 price objective on shares of Envista in a report on Friday, February 6th. William Blair raised shares of Envista from a “hold” rating to an “outperform” rating in a research note on Friday, February 6th. UBS Group increased their price objective on shares of Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d)” rating on shares of Envista in a report on Monday, December 29th. Finally, Robert W. Baird set a $30.00 target price on Envista in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Envista presently has a consensus rating of “Moderate Buy” and an average price target of $27.43.

Envista Price Performance

NYSE NVST opened at $28.99 on Wednesday. The company has a 50-day moving average price of $23.71 and a two-hundred day moving average price of $21.54. Envista has a 52 week low of $14.22 and a 52 week high of $30.42. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 103.52, a price-to-earnings-growth ratio of 1.97 and a beta of 1.01. The company has a current ratio of 2.38, a quick ratio of 2.04 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same quarter in the previous year, the firm earned $0.24 EPS. The business’s quarterly revenue was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts forecast that Envista will post 1 EPS for the current year.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 9,675 shares of the firm’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the transaction, the senior vice president directly owned 32,382 shares in the company, valued at $971,460. This trade represents a 23.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.66% of the company’s stock.

Institutional Investors Weigh In On Envista

Several hedge funds have recently made changes to their positions in the company. Holocene Advisors LP acquired a new position in shares of Envista in the second quarter worth $43,936,000. Norges Bank purchased a new stake in shares of Envista during the 4th quarter worth about $45,113,000. Alliancebernstein L.P. lifted its holdings in shares of Envista by 34.0% during the 2nd quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after buying an additional 1,547,656 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Envista by 16.7% in the 2nd quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after buying an additional 1,284,767 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Envista in the third quarter worth approximately $24,260,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.